

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
21 June 2007 (21.06.2007)

PCT

(10) International Publication Number
WO 2007/070826 A1

(51) International Patent Classification:

C07D 233/68 (2006.01) **C07D 409/12** (2006.01)
C07D 401/04 (2006.01) **C07D 409/14** (2006.01)
C07D 401/12 (2006.01) **C07D 413/14** (2006.01)
C07D 401/14 (2006.01) **C07D 417/12** (2006.01)
C07D 403/04 (2006.01) **C07D 417/14** (2006.01)
C07D 403/12 (2006.01) **C07D 471/08** (2006.01)
C07D 403/14 (2006.01) **C07D 471/18** (2006.01)
C07D 405/14 (2006.01)

Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Hopewell, New Jersey 08534 (US). **QUAN, Mimi L.** [US/US]; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Hopewell, New Jersey 08534 (US).

(74) **Agents:** **SUN, Jing G.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(21) International Application Number:

PCT/US2006/062005

(22) International Filing Date:

13 December 2006 (13.12.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/750,130 14 December 2005 (14.12.2005) US
 60/821,163 2 August 2006 (02.08.2006) US
 60/865,211 10 November 2006 (10.11.2006) US

(71) **Applicant (for all designated States except US):** **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors; and

(75) **Inventors/Applicants (for US only):** **PINTO, Donald, J.p.** [US/US]; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Hopewell, New Jersey 08534 (US). **SMALLHEER, Joanne, M.** [US/US]; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Hopewell, New Jersey 08534 (US). **CORTE, James R.** [US/US]; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Hopewell, New Jersey 08534 (US). **HU, Zilun** [CN/US]; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Hopewell, New Jersey 08534 (US). **CAVALLARO, Cullen L.** [US/US]; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Hopewell, New Jersey 08534 (US). **GILLIGAN, Paul, J.** [US/US]; c/o

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))


Published:

- with international search report
- with amended claims

Date of publication of the amended claims: 16 August 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS



(57) **Abstract:** The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L₁, M and R¹¹ are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor

IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.



WO 2007/070826 A1